Last reviewed · How we verify
Budesonide/formoterol pMDI
Budesonide/formoterol pMDI is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD). Also known as: Symbicort.
Budesonide/formoterol combines an inhaled corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.
Budesonide/formoterol combines an inhaled corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide/formoterol pMDI |
|---|---|
| Also known as | Symbicort |
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist (LABA) that stimulates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects in a single inhaled formulation.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (PHASE3)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide/formoterol pMDI CI brief — competitive landscape report
- Budesonide/formoterol pMDI updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Budesonide/formoterol pMDI
What is Budesonide/formoterol pMDI?
How does Budesonide/formoterol pMDI work?
What is Budesonide/formoterol pMDI used for?
Who makes Budesonide/formoterol pMDI?
Is Budesonide/formoterol pMDI also known as anything else?
What drug class is Budesonide/formoterol pMDI in?
What development phase is Budesonide/formoterol pMDI in?
What are the side effects of Budesonide/formoterol pMDI?
What does Budesonide/formoterol pMDI target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drugs
- Target: All drugs targeting Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance and reliever therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Also known as: Symbicort
- Compare: Budesonide/formoterol pMDI vs similar drugs
- Pricing: Budesonide/formoterol pMDI cost, discount & access